Taku Fujimura Selected Research

Pemphigus (Pemphigus Vulgaris)

3/2021	Possible roles of CXCL13/CXCR5 axis in the development of bullous pemphigoid.
12/2017	A possible interaction between periostin and CD163+ skin-resident macrophages in pemphigus vulgaris and bullous pemphigoid.
1/2014	Comparison of CD163+ CD206+ M2 macrophages in the lesional skin of bullous pemphigoid and pemphigus vulgaris: the possible pathogenesis of bullous pemphigoid.
9/2013	Induction of IL-17 producing cells and Foxp3+ regulatory T cells in areas of skin affected by localized pemphigus folliaceus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Taku Fujimura Research Topics

Disease

61	Neoplasms (Cancer) 04/2024 - 12/2006
61	Melanoma (Melanoma, Malignant) 12/2023 - 12/2006
15	Mycosis Fungoides 01/2024 - 01/2006
13	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2024 - 09/2016
11	Squamous Cell Carcinoma (Epidermoid Carcinoma) 04/2024 - 09/2014
9	Hemangiosarcoma (Angiosarcoma) 11/2023 - 01/2012
7	Lymphoma (Lymphomas) 11/2022 - 01/2004
6	Skin Neoplasms (Skin Cancer) 11/2023 - 01/2019
6	Neoplasm Metastasis (Metastasis) 02/2023 - 01/2018
5	Extramammary Paget Disease (Paget Disease, Extramammary) 01/2019 - 11/2012
5	Inflammation (Inflammations) 01/2019 - 11/2005
4	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2021 - 05/2012
4	Pemphigus (Pemphigus Vulgaris) 03/2021 - 09/2013
4	Bullous Pemphigoid (Pemphigoid) 11/2018 - 01/2014
4	Autoimmune Diseases (Autoimmune Disease) 01/2018 - 09/2012
4	Carcinoma (Carcinomatosis) 01/2017 - 09/2012
3	Drug Eruptions (Drug Eruption) 01/2023 - 05/2015
3	Dermatofibrosarcoma 10/2022 - 05/2011
3	Skin Diseases (Skin Disease) 01/2022 - 10/2013
3	Fever (Fevers) 01/2021 - 01/2018
3	Sarcoma (Soft Tissue Sarcoma) 09/2020 - 05/2013
3	Carcinogenesis 01/2020 - 09/2018
3	Disease Progression 09/2018 - 01/2016
2	COVID-19 02/2024 - 01/2022
2	Uveitis 12/2023 - 06/2018
2	Uveomeningoencephalitic Syndrome (Vogt Koyanagi Harada Syndrome) 12/2023 - 06/2018
2	Peripheral Nervous System Diseases (PNS Diseases) 02/2023 - 01/2020
2	Rheumatoid Arthritis 05/2022 - 05/2015
2	Lymphomatoid Papulosis 01/2022 - 02/2018
2	Atopic Dermatitis (Atopic Eczema) 01/2022 - 01/2017
2	Lichen Planus (Lichen Ruber Planus) 01/2021 - 10/2019
2	Necrosis 12/2020 - 04/2009
2	T-Cell Lymphoma (Lymphoma, T Cell) 01/2020 - 01/2019
2	Keratoacanthoma 01/2019 - 09/2017
2	Erythema 02/2018 - 09/2012
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2018 - 01/2017
2	Fibrosis (Cirrhosis) 01/2017 - 01/2015
2	Merkel Cell Carcinoma 10/2016 - 11/2012

Drug/Important Bio-Agent (IBA)

33	NivolumabIBA 02/2024 - 01/2016
16	ChemokinesIBA 03/2021 - 11/2015
15	IpilimumabIBA 12/2022 - 09/2016
14	Immune Checkpoint InhibitorsIBA 12/2022 - 05/2017
13	AntibodiesIBA 12/2022 - 09/2017
13	Biomarkers (Surrogate Marker)IBA 09/2022 - 01/2016
10	Bexarotene (LGD1069)FDA Link 01/2024 - 01/2017
10	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2023 - 09/2017
10	trametinibIBA 05/2022 - 02/2018
10	dabrafenibIBA 05/2022 - 02/2018
9	pembrolizumabIBA 04/2024 - 01/2018
7	PeriostinIBA 09/2021 - 01/2015
7	Interleukin-17 (Interleukin 17)IBA 01/2020 - 09/2012
6	mogamulizumabIBA 11/2022 - 01/2018
6	CytokinesIBA 01/2020 - 01/2016
6	Therapeutic UsesIBA 01/2020 - 11/2005
5	Proto-Oncogene Proteins B-rafIBA 12/2023 - 01/2019
5	Proteins (Proteins, Gene)FDA Link 04/2022 - 11/2005
5	RetinoidsIBA 01/2022 - 01/2004
5	LigandsIBA 11/2020 - 10/2018
4	Plasminogen Activator Inhibitor 1IBA 01/2024 - 01/2021
4	Messenger RNA (mRNA)IBA 03/2023 - 11/2015
4	binimetinibIBA 05/2022 - 06/2020
4	encorafenibIBA 05/2022 - 06/2020
4	Matrix Metalloproteinases (MMPs)IBA 09/2021 - 11/2012
4	InterferonsIBA 01/2021 - 01/2006
4	Denosumab FDA Link 01/2020 - 01/2017
4	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2020 - 01/2017
3	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA 12/2023 - 09/2019
3	taxaneIBA 07/2023 - 01/2023
3	Docetaxel (Taxotere)FDA Link 02/2023 - 01/2012
3	Dacarbazine (DIC)FDA LinkGeneric 12/2022 - 01/2018
3	Etoposide (VP 16)FDA LinkGeneric 11/2022 - 01/2018
3	Retinoid X Receptors (Retinoid X Receptor)IBA 01/2022 - 01/2018
3	Interleukin-23 (Interleukin 23)IBA 01/2020 - 05/2018
3	Programmed Cell Death 1 ReceptorIBA 01/2019 - 01/2018
3	Interleukin-12 (IL 12)IBA 05/2018 - 04/2004
3	RANK LigandIBA 01/2018 - 01/2016
3	PeplomycinIBA 01/2017 - 09/2014
2	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2024 - 01/2012
2	Plasminogen Activators (Plasminogen Activator)IBA 01/2024 - 11/2023
2	HLA-DRB1*04 antigenIBA 12/2023 - 06/2018
2	Paclitaxel (Taxol)FDA LinkGeneric 11/2023 - 02/2023
2	Taxoids (Taxanes)IBA 01/2023 - 01/2018
2	PlasminogenIBA 01/2023 - 01/2021
2	Cytotoxins (Cytolysins)IBA 12/2022 - 09/2020
2	Interferon Type IIBA 12/2022 - 09/2020
2	AntigensIBA 09/2022 - 09/2020
2	Tacrolimus (Prograf)FDA LinkGeneric 01/2022 - 05/2012
2	Histone Deacetylase InhibitorsIBA 09/2019 - 01/2019
2	B7-H1 AntigenIBA 03/2019 - 01/2019
2	Prednisolone (Predate)FDA LinkGeneric 11/2018 - 01/2017
2	Indicators and Reagents (Reagents)IBA 01/2018 - 01/2018
2	Imiquimod (Aldara)FDA LinkGeneric 01/2018 - 01/2017
2	Interferon-alpha (Interferon Alfa)IBA 09/2016 - 04/2007

Therapy/Procedure

61	Therapeutics 12/2023 - 02/2008
16	Immunotherapy 12/2022 - 11/2005
7	Drug Therapy (Chemotherapy) 12/2023 - 09/2014
5	Radiotherapy 11/2022 - 01/2012
5	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 09/2021 - 05/2017
3	Chemoradiotherapy 02/2023 - 01/2018
2	Phototherapy (Light Therapy) 06/2023 - 02/2018